The global pulmonary arterial hypertension (PAH) market size was valued at USD 7.5 billion in 2022. The market is projected to grow from USD 7.5 billion in 2022 to USD 10.9 billion by 2030, exhibiting a CAGR of 5.50% during the forecast period.
Read Comprehensive Overview of Report @ https://marketsnresearch.com/report/1651/global-pulmonary-arterial-hypertension-pah-market
In the upcoming years, the pulmonary arterial hypertension (PAH) market will expand due to the rising occurrences of cardiovascular and pulmonary illnesses and the aging population, which is prone to such medical conditions. Furthermore, the risks of hypertension and high blood pressure have increased due to changes in lifestyle, such as a lack of physical activity, excessive alcohol consumption, and bad eating habits. The market for pulmonary arterial hypertension (PAH) is expanding as a result of factors like this, the creation of novel orphan drugs and technologically advanced devices for the treatment of PAH, the growing public awareness of the readily available treatment options for PAH, and an innovative healthcare system.
LIST OF KEY COMPANIES PROFILED:
- United Therapeutics Corporation
- Bayer; Gilead Sciences, Inc.
- Johnson Johnson
- Viatris Inc.
- GlaxoSmithKline
- Sandoz Inc. (Novartis)
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceuticals Inc.
Read More News :
